Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 45.85
+6.80 (17.41%)
Mar 27, 2025, 4:08 PM HKT
Innovent Biologics Revenue
Innovent Biologics had revenue of 3.95B CNY in the half year ending June 30, 2024, with 76.47% growth. This brings the company's revenue in the last twelve months to 7.46B, up 48.59% year-over-year. In the year 2023, Innovent Biologics had annual revenue of 6.21B with 36.21% growth.
Revenue (ttm)
7.46B CNY
Revenue Growth
+48.59%
P/S Ratio
9.18
Revenue / Employee
1.53M CNY
Employees
4,872
Market Cap
75.11B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| WuXi Biologics | 18.39B |
| JD Health International | 61.89B |
| Alibaba Health Information Technology | 31.39B |
| Sino Biopharmaceutical | 30.72B |
| Akeso | 2.01B |
| Sichuan Kelun-Biotech Biopharmaceutical | 2.06B |
Innovent Biologics News
- 23 hours ago - Innovent to Present Preclinical Data of Multiple Novel Molecules at the 2025 AACR Annual Meeting - PRNewsWire
- 1 day ago - Innovent Announces 2024 Annual Results and Business Updates - PRNewsWire
- 4 days ago - Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer - PRNewsWire
- 8 days ago - Innovent and HUTCHMED Jointly Announce that the FRUSICA-2 Phase 2/3 Study of Sintilimab and Fruquintinib Combination Has Met Its Primary Endpoint in Advanced Renal Cell Carcinoma in China - PRNewsWire
- 13 days ago - China's First IGF-1R Monoclonal Antibody: Innovent Announces NMPA approval of SYCUME® for the Treatment of Thyroid Eye Disease - PRNewsWire
- 25 days ago - Head-to-Head Against Pembrolizumab: Innovent Announces First Patient Dosed in the First Pivotal Study of IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma - PRNewsWire
- 4 weeks ago - NMPA Accepts NDA and Grants Priority Review Designation to Innovent's Ipilimumab Injection, China's First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer - PRNewsWire
- 5 weeks ago - Innovent Receives Second Fast Track Designation from the U.S. FDA for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Squamous Non-Small Cell Lung Cancer - PRNewsWire